Severity Index of Neonatal Septicemia Using Score for Neonatal Acute Physiology (SNAP) II

Overview

To determine the effect of Score for Neonatal Acute Physiology II as a Predictor of Mortality and Organ Dysfunction in Neonates with Septicemia in the Neonatal Intensive Care Units at CHILDREN'S HOSPITAL, CAIRO UNIVERSITY and at ELGALAA Children's MILITARY HOSPITAL.

Full Title of Study: “Severity Index of Neonatal Septicemia of Cases Admitted at Neonatal Intensive Care Units at CHILDREN’S HOSPITAL, CAIRO UNIVERSITY and at ELGALAA Children’s MILITARY HOSPITAL Using Score for Neonatal Acute Physiology (SNAP) II”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 31, 2018

Detailed Description

This study will be conducted at the Neonatal intensive care Units at CHILDREN'S HOSPITAL, CAIRO UNIVERSITY and at ELGALAA Children's MILITARY HOSPITAL. Population of study & disease condition: Neonates with septicemia admitted to NICUs in CHILDREN'S HOSPITAL, CAIRO UNIVERSITY and in ELGALAA Children's MILITARY HOSPITAL. Inclusion criteria: 1. Type of patient: Neonates with septicemia. 2. Age of patient: From 0-28 Days. 3. Sex: males and females. Exclusion criteria: 1. Neonates with proved inborn error of metabolism. 2. Neonates with multiple congenital anomalies. 3. Neonates with severe birth asphyxia (APGAR score <4 at 5 minutes). Methodology in details: We will have 2 groups, each of them 50 neonates with septicemia. One group of premature neonates (32-36 weeks), the other group of full term neonates (>37 weeks). All included Patients will be subjected to the following: 1. Full history with emphasis of relevant data as follows: Date of birth, gestational age (AGA or SGA), gender, day of sepsis onset. 2. Clinical assessment: Full systems examination. 3. Diagnosis of sepsis: – By abnormal Total leucocytic count or I/T ratio or CRP with clinical Suggestion (poor feeding, hepatomegaly, apnea, tachypnea, lethargy, …). – Confirm diagnosis by blood culture. Sepsis will be considered severe if the neonate has sepsis plus one of the following: 1) cardiovascular organ dysfunction (hypotension or need for vasoactive drug) 2) 2 of the following (metabolic acidosis, increase lactic acid, oliguria, Prolonged capillary refill time) 3) Organ dysfunction (respiratory, renal, neurologic, hematologic). 4. SNAP II score: For all neonates included in the study and its data collection within 24 hours from onset of sepsis, in the form of: – Lowest mean blood pressure. – Worst ratio of pao2/fio2 – Lowest temperature. – Lowest serum PH. – Occurrence of multiple seizures. – Urine output<1 ml/kg/hour. 5. Follow up: Follow up all neonates included in the study for 14 days: for morbidity and mortality. 6. Diagnosis of organ dysfunction: Respiratory: by CXR and clinical examination. CVS: by blood pressure, capillary refill time, shock and need for inotropes. Renal: by urine output, kidney function tests. Hematology: by picture of DIC or pancytopenia. Neurology: by seizures, dilated fixed pupil. Possible Risk: None. Primary outcomes: Using Score for Neonatal Acute Physiology II as a Predictor of Mortality and Organ Dysfunction in Neonates with Septicemia. Secondary outcomes: Early anticipation of clinical manifestations of sepsis which will correlate most with poor outcome. Sample size: 100 Neonates with septicemia admitted to NICUs in CHILDREN'S HOSPITAL, CAIRO UNIVERSITY and in ELGALAA Children's MILITARY HOSPITAL.

Interventions

  • Diagnostic Test: score for neonatal sepsis
    • score for neonatal sepsis to predict morbidity

Arms, Groups and Cohorts

  • Preterm neonates
    • Neonates born between 32 and 37 weeks gestation
  • Fullterm neonates
    • Neonates born at or after 37 weeks gestation

Clinical Trial Outcome Measures

Primary Measures

  • Using Score for Neonatal Acute Physiology II as a Predictor of Mortality and Organ Dysfunction in Neonates with Septicemia.
    • Time Frame: through study completion, an average of 1 year

Secondary Measures

  • Early anticipation of clinical manifestations of sepsis which will correlate most with poor outcome.
    • Time Frame: through study completion, an average of 1 year

Participating in This Clinical Trial

Inclusion Criteria

1. Type of patient: Neonates with septicemia. 2. Age of patient: From 0-28 Days. 3. Sex: males and females. Exclusion Criteria:

1. Neonates with proved inborn error of metabolism. 2. Neonates with multiple congenital anomalies. 3. Neonates with severe birth asphyxia (APGAR score <4 at 5 minutes).

Gender Eligibility: All

Minimum Age: 1 Day

Maximum Age: 28 Days

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ahmed Mahmoud Ali Ali Youssef
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Ahmed Mahmoud Ali Ali Youssef, Doctor – Cairo University
  • Overall Official(s)
    • Nermin R Mohamed, MD, Principal Investigator, Cairo University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.